The treatment landscape of renal cell carcinoma (RCC) is rich and consists of multiple local and systemic options. However, the medical need differs broadly between localized and metastatic stages. The article by Hofman et al. in The Journal of Nuclear Medicine (1) reported successful development of a novel theranostic tracer in RCC patients.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile